Document:

Exhibit 10.30

 

July 7,
2004

 

 

Via
Facsimile 858-646-8028

and
Certified Mail

Return
Receipt Requested

 

Quidel
Corporation

10165
McKellar Court

San
Diego, CA 92121

 

Attention:  Mark Paiz, Vice President

 

RE:                              Product Supply Agreement
dated as of July 3, 1997 by and between Quidel Corporation (“Quidel”) and
Heska Corporation (“Heska”) (the  “Supply
Agreement”)

 

Dear
Mr. Paiz:

 

This
letter will confirm the agreement of Heska and Quidel to amend Section 10.1
of the Supply Agreement by adding the following proviso at the end of such Section 10.1:

 

“provided, however, that Heska may deliver written notice to Quidel on
or before March 31, 2005, that it does not wish to renew this Agreement
for any additional renewal term following expiration of the renewal term that expires
in July 2005.”

 

Please
confirm Quidel’s agreement that this letter constitutes an amendment to the
Supply Agreement pursuant to Section 14.1 thereof.

 

Very
truly yours,

 

 

	
    /s/ 
  Carol Talkington Verser

  	
   

  
	
  Carol
  Talkington Verser, Ph.D.

  	
   

  
	
  Executive
  Vice President

  	
   

  
	
  Intellectual
  Property and Business Development

  	
   

  

 

 

ACCEPTED
AND AGREED:

QUIDEL
CORPORATION

 

 

	
  By:    

  	
   /s/  Mark E. Paiz

  	
   

  
	
  Its:    

  	
   COOExhibit 10.39

 

[***] — Certain information in this exhibit have been omitted and filed
separately with the Securities and Exchange Commission.  Confidential treatment has been requested
with respect to the omitted portions.

 

AMENDMENT NO. 1 TO

SUPPLY AND LICENSE AGREEMENT

 

This
Amendment No. 1  modifies the
Supply and License Agreement between Heska Corporation and Schering-Plough
Animal Health Corporation, dated August 1, 2003 (“Original Agreement”).

 

1.                                       Appendix
A:  Appendix A to the Original
Agreement is hereby deleted in its entirety and replaced with Appendix A-1
attached hereto.

 

2.                                       Appendix
B:  Appendix B to the First Modified
Agreement is hereby deleted in its entirety and replaced with Appendix B-1
attached hereto.

 

3.                                       Appendix
D:  [***], of the Original Agreement
is hereby amended to [***]

 

[***]

[***]

[***]

 

4.                                       No
Other Changes.  Except as expressly
modified by this Amendment No. 1, all provisions of the Agreement shall
remain in full force and effect.  The
terms and conditions of this Amendment No. 1 shall control any conflict
with the terms and conditions of the Original Agreement.

 

IN
WITNESS WHEREOF, the parties have executed this Amendment by their duly
authorized representatives effective as of the last date on which this
Amendment has been duly signed by both parties.

 

SIGNED:

 

	
  Heska
  Corporation

  	
   

  	
  Schering-Plough
  Animal Health Corporation

  
	
   

  	
   

  	
   

  
	
  By:

  	
    /s/
  Carol Talkington Verser

  	
   

  	
  By: [***]

  
	
   

  	
   

  	
   

  
	
  Name: Carol
  Talkington Verser, Ph.D.

  	
   

  	
  Name: [***]

  
	
   

  	
   

  	
   

  
	
  Title: Executive
  Vice President

  	
   

  	
  Title: [***]

  
	
   

  	
   

  	
   

  
	
  Date:

  	
    August 31,
  2005

  	
   

  	
  Date:

  	
    August 24,
  2005

  
						

 

 

[***] — Certain information on this page have been omitted and
filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested
with respect to the omitted portions.

 

APPENDIX A-1

 

PRICE, MINIMUM PURCHASE SIZE AND

ANNUAL MINIMUM PURCHASE REQUIREMENT

 

1.             Product transfer price:

 

	
  Small tablets

  	
   

  	
  [***] per packet
  of six (6) tablets

  
	
  Medium tablets

  	
   

  	
  [***] per packet
  of six (6) tablets

  
	
  Large tablets

  	
   

  	
  [***] per packet
  of six (60 tablets

  

 

2.             Minimum Purchase Size:

 

	
  Small tablets

  	
   

  	
  [***] packets,
  equivalent to [***] Display Cases

  
	
  Medium tablets

  	
   

  	
  [***] packets,
  equivalent to [***] Display Cases

  
	
  Large tablets

  	
   

  	
  [***] packets,
  equivalent to [***] Display Cases

  

 

3.             Annual Minimum Purchase Requirement
per Calendar Year:

 

	
  Small tablets

  	
   

  	
  [***] packets
  equivalent to [***] Display Cases

  
	
  Medium tablets

  	
   

  	
  [***] packets
  equivalent to [***] Display Cases

  
	
  Large tablets

  	
   

  	
  [***] packets
  equivalent to [***] Display Cases

  

 

 

[***] — Certain information on this page have been omitted and
filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested
with respect to the omitted portions.

 

APPENDIX B-1

 

PRODUCT SPECIFICATIONS

 

A.            SMALL
TABLETS:

 

Labeled amount of
ivermectin, per tablet: 68 mcg

 

Labeled
amount of pyrantel (as pyrantel pamoate), per tablet: 57 mg

 

1. Appearance: Round,
brown convex tablet with bisect, approximately 0.56 inches in diameter and 1.25
grams in weight

 

2.
Identification:

 

Ivermectin:
retention times of reference standard and sample compare satisfactorily

 

Pyrantel:
retention times of reference standard and sample compare satisfactorily

 

3. Ivermectin content
(average): 90.0 to 115.0 % of labeled amount

 

4. Pyrantel content (average):
90.0 to 110.0 % of labeled amount

 

5. Microbial limits:

Salmonella: none detected

Escherichia coli: not
more than 2.2 CFU per gram

 

6. pH: 4.0 to 6.0

 

7.  [***]

 

B.            MEDIUM
TABLETS:

 

Labeled amount of
ivermectin, per tablet: 136 mcg

Labeled amount of pyrantel (as pyrantel pamoate), per
tablet: 114 mg

 

1. Appearance: Round,
brown convex tablet with no imprinting, approximately 0.75 inches in diameter
and 2.5 grams in weight

 

 

[***] — Certain information on this page have been omitted and
filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested
with respect to the omitted portions.

 

2. Identification:

Ivermectin: retention
times of reference standard and sample compare satisfactorily

Pyrantel: retention times
of reference standard and sample compare satisfactorily

 

3. Ivermectin content
(average): 90.0 to 115.0 % of labeled amount

 

4. Pyrantel content
(average): 90.0 to 110.0 % of labeled amount

 

5. Microbial limits:

Salmonella: none detected

Escherichia coli: not
more than 2.2 CFU per gram

 

6. pH: 4.0 to 6.0

 

7.  [***]

 

C.            LARGE
TABLETS:

 

Labeled amount of
ivermectin, per tablet: 272 mcg

Labeled amount of pyrantel (as pyrantel pamoate), per
tablet: 227 mg

 

1. Appearance: Round,
brown convex tablet with no imprinting, approximately 0.94 inches in diameter
and 5.0 grams in weight

 

2. Identification:

 

Ivermectin:
retention times of reference standard and sample compare satisfactorily

 

Pyrantel:
retention times of reference standard and sample compare satisfactorily

 

3. Ivermectin content
(average): 90.0 to 115.0 % of labeled amount

 

4. Pyrantel content
(average): 90.0 to 110.0 % of labeled amount

 

5. Microbial limits:

Salmonella: none detected

Escherichia coli: not
more than 2.2 CFU per gram

 

6. pH: 4.0 to 6.0

 

 

[***] — Certain information on this page have been omitted and
filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested
with respect to the omitted portions.

 

7.  [***]

 

D.  BLISTER PACKS, CARTONS AND DISPLAY CASE:

 

1. Blister Pack:  2 x 3 rectangular configuration of blisters
with one (1) tablet contained in each blister.

 

2.  Blister material:

Barrier film: 7.5
mil PVC / 2 mil ACLAR laminate.

Push-through foil:  Hueck Foils, AL201CHM, preprinted

 

3. Carton: Preprinted,
containing one (1) blister pack

 

4.  Display Case: 
Preprinted, containing ten (10) cartons.Exhibit 10.41

 

[***] — Certain information in this exhibit have been omitted and filed
separately with the Securities and Exchange Commission.  Confidential treatment has been requested
with respect to the omitted portions.

 

Amendment to Distribution Agreement

 

Between

 

Heska Corporation, 3760 Rocky Mountain Ave., Loveland, CO

80538 (“Heska”)

 

and

 

Abbott Point of Care, Abbott Laboratories Inc. (“i-Stat”)

 

This Amendment shall amend the above-referenced Distribution Agreement
dated 10/01/2004, as follows, where Heska purchases products and equipment for
distribution from I-Stat (collectively referred to herein as “Agreement”) as
set forth below.

 

The following terms shall be added to the Agreement:

 

A.) Addition of Precision PCx Blood Glucose Test Strips (“Test Strips”)
to Exhibit 1.29:

 

The following Test Strips are hereby added to the Agreement at the
prices provided in the table below:

 

	
  Precision PCx Test Strips

  	
   

  	
  Item

  Number

  	
   

  	
  UOM

  	
   

  	
  Price

  (Case)

  	
   

  	
  Price

  (Box)

  	
   

  
	
  Precision PCx G2b Strip (100 count box)

  	
   

  	
  98757-19

  	
   

  	
  1 Case (6 x
  100 count boxes)

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  
	
  Precision PCx Plus G3 Strip (100 count box)

  	
   

  	
  80063-01

  	
   

  	
  1 Case (6 x
  100 count boxes)

  	
   

  	
  $

  	
  [***]

  	
   

  	
  $

  	
  [***]

  	
   

  

 

B.) i-Stat Cartridge Rebate

 

The Cartridge rebate, as defined by the Agreement, dated 10/01/2004 in Section 3.6.1,
does not apply to any purchases of the Test Strips by Heska.

 

All other terms and conditions stated in the Agreement shall remain in
effect throughout the term of the Agreement or as modified by the parties in
writing.

 

The Effective Date of this Amendment shall be the date that it has been
signed by authorized representatives of both Heska and i-Stat.

 

This Amendment is herby incorporated into and made a part of the
Agreement.

 

 

[***] — Certain information on this page have been omitted and
filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested
with respect to the omitted portions.

 

In Witness Whereof, the parties have caused this Amendment to be
executed by their respective authorized representatives.

 

	
   

  Heska Corporation:

  	
   

  	
  Offered by:

  Abbott Laboratories Inc.

  Abbott Point of Care

  
	
  By:

  	
  /s/ John R. Flanders

  	
   

  	
  By:

  	
  [***]

  
	
  Print Name:

  	
  John R. Flanders

  	
   

  	
  Print Name:

  	
  [***]

  
	
  Title:

  	
  VP, General Counsel

  	
   

  	
  Title:

  	
  Divisional Vice President

  
	
  Date:

  	
  January 31, 2007

  	
   

  	
  Date:

  	
  February 5, 2007

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]